Hematol Oncol 2019 Oct 11;37(4):493-495. Epub 2019 Sep 11.
Unit of Hematology, Azienda Ospedaliera Universitaria Senese & University of Siena, Siena, Italy.
Leuk Lymphoma 2021 Jun 11:1-13. Epub 2021 Jun 11.
Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
We assessed event-free (EFS) and overall (OS) survival in 676 incident cases of childhood Hodgkin (HL) and non-Hodgkin (NHL) lymphoma actively registered in Greece (1996-2019). HL-OS was 96% and NHL-OS 85%, whereas HL-EFS was 86% and NHL-EFS was 81%, notably similar to the respective OS rates (HL: 95%, NHL: 85%) in developed countries. For HL, older age at diagnosis, high maternal education and close proximity to treatment centers were linked to remarkably favorable outcomes. Read More
J Cachexia Sarcopenia Muscle 2021 Jun 11. Epub 2021 Jun 11.
Division of Hematology, ASST Spedali Civili, Brescia, Italy.
Background: Elderly classical Hodgkin lymphoma (cHL) (ecHL) is a rare disease with dismal prognosis and no standard treatment. Fitness-based approaches may help design appropriate treatments. Sarcopenia has been associated with an increased risk of treatment-related toxicities and worse survival in various solid tumours, but its impact in ecHL is unknown. Read More
Histol Histopathol 2021 Jun 11:18351. Epub 2021 Jun 11.
Department of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma usually characterized by t(11;14) (q13;q32), or CCND1 translocation and Cyclin D1 over expression. A very small subset of MCL may lack the t(11;14) (q13;q32) translocation and Cyclin D1 over expression, but show alternative translocations involving CCND2 and CCND3, and over expression of SOX11. In general, MCL has been considered a very aggressive and incurable lymphoma and patients with MCL usually have a poor prognosis. Read More
Front Oncol 2021 25;11:664421. Epub 2021 May 25.
Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Background: The use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). Despite improved outcomes, high relapse rate remains a challenge to overcome. Here, we report the clinical results and the pharmacokinetics of bispecific CD19/22 CAR T in patients with R/R B-NHL. Read More
Front Oncol 2021 25;11:658358. Epub 2021 May 25.
Department of Radiation Oncology, CyberKnife and Radiation Therapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Introduction: Consolidation radiotherapy in intermediate stage Hodgkin´s lymphoma (HL) has been the standard of care for many years as involved field radiotherapy (IFRT) after chemotherapy. It included initially involved region(s). Based on randomized studies, radiation volumes could be reduced and involved site radiation therapy (ISRT) became the new standard. Read More